ATE223967T1 - Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln - Google Patents

Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln

Info

Publication number
ATE223967T1
ATE223967T1 AT97948268T AT97948268T ATE223967T1 AT E223967 T1 ATE223967 T1 AT E223967T1 AT 97948268 T AT97948268 T AT 97948268T AT 97948268 T AT97948268 T AT 97948268T AT E223967 T1 ATE223967 T1 AT E223967T1
Authority
AT
Austria
Prior art keywords
cell
microparticles
mediated
molecules
pressure
Prior art date
Application number
AT97948268T
Other languages
English (en)
Inventor
Micheal J Mann
Victor J Dzau
Gary H Gibbons
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE223967T1 publication Critical patent/ATE223967T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
    • A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons pressurised by means of pistons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/04—Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/14—Bags
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/40—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Sustainable Development (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Clinical Laboratory Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT97948268T 1996-11-07 1997-11-07 Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln ATE223967T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/745,023 US5922687A (en) 1995-05-04 1996-11-07 Intracellular delivery of nucleic acids using pressure
PCT/US1997/020696 WO1998020109A1 (en) 1996-11-07 1997-11-07 Pressure-mediated intracellular delivery of molecules or microparticles

Publications (1)

Publication Number Publication Date
ATE223967T1 true ATE223967T1 (de) 2002-09-15

Family

ID=24994918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97948268T ATE223967T1 (de) 1996-11-07 1997-11-07 Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln

Country Status (15)

Country Link
US (1) US5922687A (de)
EP (2) EP0944715B1 (de)
JP (3) JP2001505419A (de)
KR (1) KR100449330B1 (de)
CN (1) CN1109749C (de)
AT (1) ATE223967T1 (de)
AU (1) AU736298B2 (de)
BR (1) BR9713334A (de)
CA (1) CA2271244C (de)
DE (1) DE69715449T2 (de)
DK (1) DK0944715T3 (de)
ES (1) ES2183221T3 (de)
IL (1) IL129808A (de)
PT (1) PT944715E (de)
WO (1) WO1998020109A1 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040165A2 (en) 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
US6627616B2 (en) * 1995-12-13 2003-09-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US7803782B2 (en) * 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US7507722B1 (en) 1999-11-05 2009-03-24 Roche Madison Inc. Intravascular delivery of nucleic acid
US20040259828A1 (en) * 1995-12-13 2004-12-23 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US20020001574A1 (en) * 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US6379966B2 (en) * 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US6582392B1 (en) 1998-05-01 2003-06-24 Ekos Corporation Ultrasound assembly for use with a catheter
US6676626B1 (en) 1998-05-01 2004-01-13 Ekos Corporation Ultrasound assembly with increased efficacy
US7435723B2 (en) * 1997-11-21 2008-10-14 Mirus Bio Corporation Process for delivery of polynucleotides to the prostate
US6699231B1 (en) 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6722370B1 (en) * 1998-07-17 2004-04-20 Corgentech, Inc. Delivery of a composition to the liver by utilizing the portal vein
EP1113836A4 (de) * 1998-09-14 2008-01-23 Mirus Bio Corp Verfahren zur freigabe von nukleinsäure an herzgewebe
EP1161547A4 (de) * 1999-02-26 2002-10-02 Mirus Corp Intravaskuläre verabreichung einer nicht-viralen nukleinsäure
EP1194449B1 (de) * 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitoren des memapsin 2 und ihre verwendung
ES2269199T3 (es) 1999-11-05 2007-04-01 Mirus Bio Corporation Suministro intravascular de acido nucleico.
US7642248B2 (en) * 1999-11-05 2010-01-05 Roche Madison Inc Devices and processes for distribution of genetic material to mammalian limb
US7214369B2 (en) * 2003-05-05 2007-05-08 Mirus Bio Corporation Devices and processes for distribution of genetic material to mammalian limb
EP2177534A3 (de) 1999-11-18 2010-07-14 Pharmexa Inc. Heteroklitische Analoga von Klasse-i Epitopen
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US6346098B1 (en) 2000-03-07 2002-02-12 The Board Of Trustees Of The Leland Stanford Junior University Methods and kits for locally administering an active agent to an interstitial space of a host
EP1278541A1 (de) * 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Verbesserung der immunogenität bei der verwendung einer kombination von dns und vacciniavirus-vektor impfstoffen
DE60138465D1 (de) 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
AU2001280789A1 (en) * 2000-07-25 2002-02-05 The Board Of Trustees Of The Leland Stanford Junior University Non-viral linear dna vectors and methods for using the same
EP2022797A3 (de) 2000-08-28 2011-11-09 Agensys, Inc. Nukleinsäure und entsprechendes Protein mit der Bezeichnung 85P1B3 für die Behandlung und den Nachweis von Krebs
WO2002066611A2 (en) * 2001-02-16 2002-08-29 The Board Of Trustees Of The Leland Stanford Junior University Minimal plasmid vectors that provide for persistent and high level gene expression and methods for using the same
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP1573024A4 (de) 2001-04-10 2007-08-29 Agensys Inc Nukleinsäuren und diesen entprechende, für die behandlung und den nachweis verschiedener krebserkrankungen geeignete proteine
WO2003010180A1 (en) 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
EP1721977A3 (de) 2001-09-17 2008-10-15 PDL BioPharma, Inc. Verfahren zur Krebsdiagnose, Zusammensetzungen und Screening-verfahren für Krebsmodulatoren
US7220239B2 (en) 2001-12-03 2007-05-22 Ekos Corporation Catheter with multiple ultrasound radiating members
US7141044B2 (en) * 2001-12-11 2006-11-28 Ekos Corporation Alternate site gene therapy
DE10211589A1 (de) * 2002-03-15 2003-10-02 Steffen-Sebastian Bolz In vitro-Transfektion und Langzeitkultivierung von isolierten Organen
US8226629B1 (en) 2002-04-01 2012-07-24 Ekos Corporation Ultrasonic catheter power control
US20030204167A1 (en) * 2002-04-24 2003-10-30 Johnson Lanny L. Device for delivering liquid medications, nutrients or gases to local tissue
AU2003301841A1 (en) * 2002-05-01 2004-06-07 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
US20030228691A1 (en) * 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7589059B2 (en) * 2002-07-26 2009-09-15 Roche Madison Inc. Delivery of molecules and complexes to mammalian cells in vivo
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
EP2801614B1 (de) 2002-08-29 2019-05-15 The Board of Trustees of the Leland Stanford Junior University Zirkuläre Nukleinsäurevektoren sowie Verfahren zur Herstellung und Verwendung davon
US6921371B2 (en) 2002-10-14 2005-07-26 Ekos Corporation Ultrasound radiating members for catheter
AU2002352976B2 (en) 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
CA2860151A1 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
AU2004263823B2 (en) 2003-05-30 2008-09-18 Agensys, Inc. Prostate stem cell antigen (PSCA) variants and subsequences thereof
ATE557099T1 (de) * 2003-09-05 2012-05-15 Genencor Int Hpv cd8+ t-zell-epitope
WO2005035547A2 (en) * 2003-10-06 2005-04-21 Corgentech, Inc. E2f oligonucleotide decoy molecules
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
JP2007520481A (ja) * 2004-01-15 2007-07-26 アルザ・コーポレーシヨン 治療薬を送達するためのリポソーム組成物
GB0406728D0 (en) * 2004-03-25 2004-04-28 Hydrodynamic Gene Delivery Ltd Gene therapy
PT1747023E (pt) 2004-05-04 2011-04-11 Univ Leland Stanford Junior Métodos e composições para reduzir quantidades de genoma viral numa célula alvo
WO2005112620A2 (en) * 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
RU2381234C2 (ru) 2004-05-28 2010-02-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками psca
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
EP1799835A4 (de) * 2004-08-23 2009-05-13 Hong Bock Lee Verfahren zum gentransfer in die organellen von zellen: direkter gentransfer in mitochondrien
US20070036740A1 (en) * 2004-10-06 2007-02-15 Reed Kenneth C Modulation of hair growth
EP1807514A1 (de) * 2004-10-22 2007-07-18 Benitec, Inc. Therapeutische rnai für behandlung von psoriasis
US20060115462A1 (en) * 2004-12-01 2006-06-01 Vladimir Subbotin Direct DNA delivery to bone cells
AU2006204120A1 (en) * 2005-01-06 2006-07-13 Benitec, Inc. RNAi agents for maintenance of stem cells
DK2325306T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide
EP2289532A1 (de) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitop Peptide, die vom Vascular Endothelial Growth Factor Rezeptor 1 abgeleitet wurden und Impfstoffe, die diese enthalten
EP3300739A3 (de) 2005-03-31 2018-07-18 Agensys, Inc. An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
US20060292159A1 (en) * 2005-06-08 2006-12-28 Ranscht Barbara E Methods for the inhibition of neovascularization and cancer metastasis
JP5095603B2 (ja) 2005-07-27 2012-12-12 オンコセラピー・サイエンス株式会社 結腸癌関連遺伝子tom34
WO2007021886A2 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
US20070143195A1 (en) * 2005-12-15 2007-06-21 Bell Ryan B Systems and methods for evaluating terms of a deal to purchase a vehicle
US20070173470A1 (en) * 2006-01-23 2007-07-26 Chi-Hung Lin Methods for delivering extracellular target into cells
CA2915560A1 (en) 2006-10-17 2008-04-24 Tomoaki Fujioka Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
US10182833B2 (en) 2007-01-08 2019-01-22 Ekos Corporation Power parameters for ultrasonic catheter
TWI494319B (zh) 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
US9043994B2 (en) * 2007-03-13 2015-06-02 Massachusetts Institute Of Technology Cre-lox based gene knockdown constructs and methods of use thereof
TW201425333A (zh) 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌8胜肽及包含此胜肽之疫苗
PL2476689T3 (pl) 2007-05-10 2016-04-29 Agilent Technologies Inc Tiowęglowe grupy zabezpieczające do syntezy RNA
ES2471118T3 (es) 2007-06-22 2014-06-25 Ekos Corporation Método y aparato para el tratamiento de hemorragias intracraneales
EP3085707B1 (de) 2007-11-01 2019-02-27 Mayo Foundation for Medical Education and Research Hla-dr-bindende peptide und deren anwendungen
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
JP5757863B2 (ja) 2008-05-19 2015-08-05 アドバクシス インコーポレイテッド 異種抗原のための二重送達システム
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
CA2728385C (en) 2008-06-17 2017-05-09 The Governing Council Of The University Of Toronto Device for investigation of a flow conduit
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
CN102083975A (zh) 2008-07-03 2011-06-01 利兰·斯坦福青年大学托管委员会 小环dna载体制剂及其制备方法和使用方法
JP5764822B2 (ja) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのprmt1
EP2352747A1 (de) * 2008-10-23 2011-08-10 Intervet International BV Lawsonia-intrazellularis-impfstoffe
KR101727333B1 (ko) 2008-11-26 2017-04-14 추가이 세이야쿠 가부시키가이샤 베시클 제제
EP2368989A4 (de) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd Oligoribonukleotid- bzw. peptidnukleinsäure zur hemmung der aktivität des hepatitis-c-virus
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1胜肽以及含此胜肽之疫苗
EP2405959A4 (de) * 2009-03-13 2013-10-16 Univ Tufts Verfahren, vorrichtungen und kits zur einführung von genetischem material in lebende zellen
US9017991B2 (en) 2009-03-13 2015-04-28 Tufts University Methods tip assemblies and kits for introducing material into cells
KR101744514B1 (ko) 2009-03-18 2017-06-08 온코세라피 사이언스 가부시키가이샤 Neil3 펩티드 및 이를 포함하는 백신
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Cdc45l胜肽與含此胜肽之疫苗
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
US8933014B2 (en) 2010-03-11 2015-01-13 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
US11020444B2 (en) * 2010-04-23 2021-06-01 Scicotec Gmbh Transluminal delivery of viruses for treatment of diseased tissue
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
US9458447B2 (en) 2011-08-12 2016-10-04 Oncotherapy Science, Inc. MPHOSPH1 peptides and vaccines including the same
RU2633503C2 (ru) 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
WO2014010231A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
EP2872531A4 (de) 2012-07-10 2016-04-06 Oncotherapy Science Inc Ly6k-epitopenpeptide für th1-zellen sowie impfstoffe damit
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ube2tペプチドおよびそれを含むワクチン
CA3106271A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Kntc2胜肽及含此胜肽之疫苗
WO2014151888A1 (en) 2013-03-15 2014-09-25 The Regents Of The University Of California High-throughput cargo delivery into live cells using photothermal platforms
WO2014153636A1 (en) 2013-03-27 2014-10-02 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
US10472651B2 (en) 2014-03-28 2019-11-12 The Regents Of The University Of California Efficient delivery of large cargos into cells on a porous substrate
US10081816B1 (en) 2014-07-03 2018-09-25 Nant Holdings Ip, Llc Mechanical transfection devices and methods
US10760040B1 (en) 2014-07-03 2020-09-01 NanoCav, LLC Mechanical transfection devices and methods
US10576097B2 (en) 2014-08-04 2020-03-03 Oncotherapy Science, Inc. URLC10-derived peptide and vaccine containing same
JP6700512B2 (ja) 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Cdca1由来ペプチドおよびそれを含むワクチン
EP3178838B1 (de) 2014-08-04 2019-09-18 OncoTherapy Science, Inc. Koc1-abgeleitetes peptid und impfstoff damit
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
US20180066223A1 (en) 2015-04-17 2018-03-08 Xcell Biosciences, Inc. Cancer cell enrichment system
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
CN107708581B (zh) 2015-06-10 2021-11-19 Ekos公司 超声波导管
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
WO2017223199A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
US10533189B2 (en) * 2016-09-20 2020-01-14 The Chinese University Of Hong Kong Highly specific delivery of polynucleotides to the cell nucleus via compression
CN111032134B (zh) * 2017-06-30 2024-02-13 阿维塔斯有限公司 电喷雾导管
US12398360B2 (en) * 2018-06-01 2025-08-26 Avectas Limited Cell engineering platform
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN118139663A (zh) * 2021-06-24 2024-06-04 阿维塔斯有限公司 喷雾喷嘴
CN114736796A (zh) * 2021-12-13 2022-07-12 湖北嘉士医疗科技有限公司 一种旋转阀芯组合的核酸检测试剂盒
US20250065080A1 (en) * 2021-12-23 2025-02-27 Aldevron, Llc Devices and methods for hollow tissue electrotransfer
WO2025024923A1 (en) * 2023-07-28 2025-02-06 Henderson Jeffrey T Method, system and apparatus for the introduction of materials across lipid membranes using modifications in hydrostatic pressure
US20250327090A1 (en) * 2024-04-23 2025-10-23 TransCytos, LLC Devices and Methods for Transfection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5584803A (en) * 1991-07-16 1996-12-17 Heartport, Inc. System for cardiac procedures
US5766901A (en) * 1995-05-04 1998-06-16 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for delivering a nucleotide into cell nuclei

Also Published As

Publication number Publication date
JP2008054681A (ja) 2008-03-13
AU7002098A (en) 1998-05-29
ES2183221T3 (es) 2003-03-16
EP0944715B1 (de) 2002-09-11
PT944715E (pt) 2003-01-31
EP0944715A4 (de) 1999-12-22
IL129808A0 (en) 2000-02-29
IL129808A (en) 2004-06-20
JP2008237221A (ja) 2008-10-09
EP1279412A3 (de) 2003-12-17
CA2271244A1 (en) 1998-05-14
WO1998020109A1 (en) 1998-05-14
CA2271244C (en) 2008-09-02
CN1109749C (zh) 2003-05-28
HK1022711A1 (en) 2000-08-18
DE69715449D1 (de) 2002-10-17
DK0944715T3 (da) 2002-12-30
EP0944715A1 (de) 1999-09-29
JP2001505419A (ja) 2001-04-24
DE69715449T2 (de) 2003-07-31
CN1244213A (zh) 2000-02-09
KR20000053164A (ko) 2000-08-25
US5922687A (en) 1999-07-13
BR9713334A (pt) 2000-05-09
EP1279412A2 (de) 2003-01-29
AU736298B2 (en) 2001-07-26
KR100449330B1 (ko) 2004-09-18

Similar Documents

Publication Publication Date Title
DE69715449D1 (de) Druckvermittelte, intrazellulaere verabreichung von molekuelen oder mikropartikeln
RU94014623A (ru) Состав и способ отделения, разделения и концентрирования требуемых ионов из растворов
ATE250426T1 (de) Verwendung von verbindungen die an ein zytoplasmatischen dipeptidase binden zur potenzierung des immunantworts
NO931689D0 (no) Anordning for elektrokjemisk syntese for "in-line" og "off-line", bleking, oksidasjon og desinfeksjon av organiske sstoffer i vaesker.
FR2713444B1 (fr) Composition liquide désinfectante et ses utilisations.
KR920004281A (ko) 폐수처리 공정에서 고-액분리 및 농축방법
CA2004068A1 (en) Hair analysis method
Giffin The benefits and detriments of ability grouping and its effectiveness
Occulto Writing in the biology classroom
Welshans A comparison of science process skills of fourth grade students using alternative assessment
Wallace The efficacy of retaining students in the early primary grades
Hughes An analysis on the opinions of teachers toward homework
Jewell An analysis of teacher opinions and practice regarding the use of African American children's literature in the elementary classroom
Brown A quantitative analysis of the effectiveness of LOGO as an instructional aid for teaching mechanics in physics
Lyons An analysis of the attitudes of fifth grade social studies students toward the use of cooperative learning techniques
Abou Jaoude Plastic analysis of rigid frames using micro computer graphics
McMahon An analysis of teaching spelling by using high frequency words
Meyer The use of behavior therapy as treatment for hyperactivity in severe behavioral handicap students
Newhouse Handbook for the implementation of aesthetics in the Art I curriculum in Beavercreek High School
Long An investigation of self-chosen instructional strategies for the remediation of handwriting
Beck Split sessions and science achievement of intermediate students
TW290665B (en) Information processing method of compressing or decompressing bit map font data and device thereof
Gerardi Learning centers in language arts and mathematics for first grade teachers
O'Connor An analysis of calculus students' attitudes toward cooperative learning
Hershey Using sustained silent reading to develop independent reading habits and attitudes in elementary students

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0944715

Country of ref document: EP

REN Ceased due to non-payment of the annual fee